Cell therapy and other neuroregenerative strategies in Parkinson's disease (I);Terapia celular y otras estrategias neurorregenerativas en la enfermedad de Parkinson (I)

Revista de Neurologia

Volumn 41, Issue 10, 2005, Pages 604-614

  Mínguez Castellanos, Adolfo ^a   Escamilla Sevilla, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cell therapy; GDNF; Neuroregeneration; Neurorestoration; Neurotrophic factors; Parkinson's disease; Transplantation

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; DOPAMINE; NERVE GROWTH FACTOR;

ADRENAL MEDULLA; CELL THERAPY; DOPAMINERGIC SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; MORBIDITY; MORTALITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; STEM CELL; STEREOTAXIC SURGERY; TREATMENT FAILURE; TREATMENT OUTCOME; CORPUS STRIATUM; FETAL TISSUE TRANSPLANTATION; GENE THERAPY; METABOLISM; NERVE REGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ADRENAL MEDULLA; CORPUS STRIATUM; DOPAMINE; FETAL TISSUE TRANSPLANTATION; GENE THERAPY; HUMANS; NERVE GROWTH FACTORS; NERVE REGENERATION; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 33644827324     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4110.2005245     Document Type: Review

References (121)

1. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med 1998; 339: 1044-53.
2. De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, López-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: The Europarkinson Collaborative Study. J Neurol Neurosurg Psychiatry 1997; 62: 10-5.
3. Benito-León J, Porta-Etessam J, Bermejo F. Epidemiología de la enfermedad de Parkinson. Neurología 1998; 13 (Supl 1): 2-9.
4. Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen-Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
5. Björklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177: 555-60.
6. Perlow MJ, Freed WJ, Hoffer BJ, Seiger Å, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979; 204: 643-7.
7. Björklund A, Dunnett SB, Stenevi U, Lewis ME, Iversen SD. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res 1980; 199: 307-33.
8. Björklund A, Stenevi U, Dunnett SB, Iversen SD. Functional reactivation of the deafferented neostriatum by nigral transplants. Nature 1981; 289: 497-9.
9. Dunnett SB, Björklund A, Stenevi U, Iversen SD. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. Brain Res 1981; 215: 147-61.
10. Freed WJ, Morihisa J, Spoor E, Hoffer B, Olson L, Seiger Å. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour. Nature 1981; 292: 351-2.
11. Herrera-Marchitz M, Stromberg I, Olsson D, Ungestedt U, Olson L. Adrenal medullary implants into the dopamine denervated rat striatum: acute behaviour as a function of graft amount and location and its modulation by neuroleptics. Brain Res 1984; 297: 53-61.
12. Redmond DE, Sladek JR Jr, Roth RH, Collier TJ, Elsworth JD, Deutch AY, et al. Fetal neuronal grafts in monkeys given methyl-phenyltetrahydro-pyridine. Lancet 1986; 1: 1125-7.
13. Sladek JR, Redmond DE, Collier TJ, Haber SN, Elsworth JD, Deutch AY, et al. Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. Prog Brain Res 1987; 71: 309-22.
14. Bakay RAE, Barrow DL, Fiandaca MS, Iuvone PM, Schiff A, Collins DC. Biochemical and behavioural correction of MPTP-like syndrome by fetal cell transplantation. Ann NY Acad Sci 1987; 495: 623-38.
15. Bankiewicz KS, Plunkett RJ, Kopin IJ, Jacobowitz DM, London WT, Olfield E. Transient behavioural recovery in hemiparkinsonian primates after adrenal medullary allografts. Prog Brain Res 1988, 78: 543-50.
16. Hansen JT, Kordower JH, Fiandaca MS, Klao SS, Notter MFD, Gash DM. Adrenal medullary autografts into the basal ganglia of Cebus monkeys: grafts viability and fine structure. Exp Neurol 1988; 102: 65-75.
17. Freund TF, Bolam JP, Björklund A, Stenevi U, Dunnett SB, Powell JF, et al. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immnuocytochemical study. J Neurosci 1985; 5: 603-16.
18. Strecker RE, Sharp T, Brundin P, Zetterström T, Ungerstedt U, Björklund A. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 1987; 22: 169-78.
19. Dunnett SB, Hernández TD, Summerfield A, Jones GH, Arbuthnott G. Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues. Exp Brain Res 1988; 71: 411-24.
20. Brundin P, Widner H, Nilsson OG, Strecker RE, Bjorklund A. Intracerebral xenografts of dopamine neurons: the role of immunosuppression and the blood-brain barrier. Exp Brain Res 1989; 75: 195-207.
21. Bankiewicz KS, Plunkett RJ, Jacobowitz DM, Porrino L, Di Porzio U, London WT, et al. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism: histochemical and behavioral studies. J Neurosurg 1990; 72: 231-44.
22. Strömberg I, Herrera-Marschitz M, Ungerstedt U, Ebendal T, Olson L. Chronic implants of chromafin tissue into the dopamine-denervated striatum: effects of NGF on graft survival, fiber growth and rotation behaviour. Exp Brain Res 1985; 60: 335-49.
23. Bing GY, Notter MF, Hansen JT, Kellogg C, Kordower JH, Gash DM. Cografts of adrenal medulla with C6 glioma cells in rat with 6-hydroxydopamine-induced lesions. Neuroscience 1990; 34: 687-97.
24. Kordower JH, Fiandaca MS, Notter MFD, Hansen JT, Gash DM. NGF-like trophic support from peripheral nerve for grafted rhesus adrenal chromaffin cells. J Neurosurg 1990; 73: 418-28.
25. Watts RL, Mandir A, Bakay RAE. Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: behavioural and anatomical assessment. Cell Transplant 1995; 4: 27-38.
26. Backlund EO, Grandberg PO, Hamberger B, Kuntsson E, Martensson A, Goran S, et al. Transplantation of adrenal medullary tissue to striatum in Parkinsonism: first clinical trials. J Neurosurg 1985; 62: 169-73.
27. Lindvall O, Backlund EO, Farde L, Sedwall G, Freedman R, Hoffer BJ, et al. Transplantation for Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol 1987; 22: 457-68.
28. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001; 2: 325-32.
29. Madrazo I, Drucker-Colin R, Díaz V, Martínez-Mata J, Torres C, Becerril J. Open microsurgical autograft of the adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med 1987; 316: 831-4.
30. Madrazo I, Franco-Bourland R, Ostrosky-Solís F, Aguilera M, Cuevas C, Álvarez F, et al. Neural trasplantation (auto-adrenal, fetal nigral and fetal adrenal) in Parkinson's disease: the Mexican experience. Prog Brain Res 1990; 82: 593-602.
31. López-Lozano JJ, Mata M, Bravo G, Grupo de Trasplantes Neurales de la Clínica Puerta de Hierro. Trasplantes neurales en la enfermedad de Parkinson: experiencia de la Clínica Puerta de Hierro y estado actual. Neurología 2000; 15 (Supl 5): 62-79.
32. Penn RD, Goetz CG, Taner CM, Klawans HL, Stannon KM, Comella CL, et al. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery 1988; 22: 999-1004.
33. Kelly P, Ahlskog E, Van Heerden J, Carmichael SW, Studdard SL, Bell GN. Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease. Mayo Clin Proc 1989; 64: 282-90.
34. Jankovic J, Grossman R, Goodman C, Pirozzolo F, Schneider L, Zhu Z, et al. Clinical, biochemical and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology 1989; 39: 1227-34.
35. Lieberman A, Ransohoff J, Berczeller P, Brous P, Eng K, Goldstein M, et al. Adrenal medullary transplants as a treatment for advanced Parkinson's disease. Acta Neurol Scand 1989; 80 (Supl. 126): 189-96.
36. López-Lozano JJ, Bravo G, Abascal J, CPH Neural Transplantation Group. A long-term study of Parkinson's patients subjected to autoimplants of perfused adrenal medulla into the caudate nucleus. Transplant Proc 1990; 22: 2243-6.
37. Jiao SS, Ding YJ, Zhang WC, Cao JK, Zhang GF, Zhang ZM, et al. Adrenal medullary autografts in patients with Parkinson's disease. N Engl J Med 1989; 321: 324-5.
38. Cahill DW, Olanow CW. Autologous adrenal medulla to caudate nucleus transplantation in advanced Parkinson's disease: 18 months results. Prog Brain Res 1990; 82: 637-42.
39. Apuzzo ML, Neal JH, Waters CH, Appley AJ, Boyd SD, Couldwell WT, et al. Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observations. Neurosurgery 1990; 26: 746-57.
40. Goetz CG Stebbins, Klawans HL, Koller WC, Grossman RG, Bakay RAE, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology 1991; 41: 1719-22.
41. López-Lozano JJ, Brera B, Abascal J, Bravo G. Preparation of adrenal medullary tissue for transplantation in Parkinson's disease: a new procedure. J Neurosurg 1989; 71: 452-4.
42. Madrazo I, Franco-Bourland R, Ostrosky-Solís F, Aguilera M, Cuevas C, Zamorano C, et al. Fetal homotransplants (ventral mesencephalon and adrenal tissue) to the striatum of parkinsonian subjets. Arch Neurol 1990; 47: 1281-5.
43. Allen GS, Burns RS, Tulipan NB, Parker RA. Adrenal medullary transplantation to the caudate nucleus in Parkinson's disease: initial clinical results in 18 patients. Arch Neurol 1989; 46: 487-91.
44. Goetz CG, Olanow CW, Koller WC, Penn RD, Cahilll D, Morantz R, et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 1989; 320: 337-41.
45. Goetz CG, Tanner CM, Penn RD, Stebbins GT III, Gilley DW, Shannon KM, et al. Adrenal medullary transplants to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology 1990; 40: 273-6.
46. López-Lozano JJ, Bravo G, Abascal J, CPH Neural Transplantation Group. Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's disease. J Neurosurg 1991; 75: 234-43.
47. Ostrosky-Solís F, Quintanar L, Madrazo I, Drucker-Colin R, Franco-Bourland R, León-Meza V. Neuropsychological effects of brain autograft of adrenal medullary tissue for the treatment of Parkinson's disease. Neurology 1988; 38: 1442-50.
48. Waxman MJ, Morantz RA, Koller WC, Paone DB, Nelson PW. High incidence of cardiopulmonary complications associated with implantation of adrenal medullary tissue into the caudate nucleus in patients with advanced neurologic disease. Crit Care Med 1991; 19: 181-6.
49. Freed WJ, Cannon-Spoor HE, Krauthamer E. Intrastriatal adrenal medulla grafts in rats: long-term survival and behavioral effects. J Neurosurg 1986; 65: 664-70.
50. Guttman M, Burns RS, Martin WRW, Peppard RF, Adam MJ, Ruth TJ, et al. PET studies of parkinsonian patients treated with autologous adrenal implants. Can J Neurol Sci 1989; 16: 305-9.
51. Hurtig H, Joyce J, Sladek JR Jr, Trojanowski JQ. Postmortem analysis of adrenal medulla to caudate autograft in a patient with Parkinson's disease. Ann Neurol 1989; 25: 607-14.
52. Waters C, Itabashi HH, Apuzzo MLJ, Weiner LP. Adrenal to caudate transplantation: a post-mortem study. Mov Disord 1990; 5: 248-50.
53. Kordower JH, Cochran E, Penn RD, Goetz CG. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Ann Neurol 1991; 29: 405-12.
54. Peterson DI, Price ML, Small CS. Autopsy findings in a patient who had an adrenal-to-brain transplant for Parkinson's disease. Neurology 1989; 39: 235-8.
55. Hirsch EC, Duyckaerts C, Javoy-Agid F, Hauw JJ, Agid Y. Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? Ann Neurol 1990; 27: 676-82.
56. Forno LS, Langston JW. Unfavourable outcome of adrenal medullary transplant for Parkinson's disease. Acta Neuropathol 1991; 81: 691-4.
57. Olson L, Backlund EO, Ebendal T, Freedman R, Hamberger B, Hanson P, et al. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease: one-year follow-up of first clinical trial. Arch Neurol 1991; 48: 373-81.
58. López-Lozano JJ, Bravo G, Abascal J, Brera B, Millan I, CPH Neural Transplantation Group. Clinical outcome of cotransplantation of peri pheral nerve and adrenal medulla in patients with Parkinson's disease. J Neurosurg 1999; 90: 875-82.
59. Watts RL, Subramanian T, Freeman A, Goetz GC, Penn RD, Stebbins GT, et al. Effect of stereotaxic intraestriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: two year follow-up study. Exp Neurol 1997; 147: 510-7.
60. Date I, Imaoka T, Miyohi Y, Ono T, Asari S, Ohmoto T. Chromaffin cel survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. J Neurosurg 1996; 84: 685-9.
61. Hallett M, Litvan I, the Task Force on Surgery for Parkinson's Disease. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Nerology. Neurology 1999; 53: 1910-21.
62. Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C, the Task Force commissioned by The Movement Disorder Society. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17 (Suppl 4): S148-55.
63. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Åstedt B, Widner H, et al. Human fetal dopamine neurons grafted into striatum in two patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46: 615-31.
64. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, et al. Grafts of fetal dopamine neurons survives and improve motor function in Parkinson's disease. Science 1990; 247: 574-7.
65. Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155-65.
66. Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brundin P, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-80.
67. Hoffer BJ, Leenders KL, Young D, Gerhardt G, Zerbe GO, Bygdeman M, et al. Eighteen-month course of two patients with grafts of fetal dopamine neurons for Parkinson's disease. Exp Neurol 1992; 118: 243-52.
68. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
69. Sawle GV, Bloomfield PM, Björklund A, Brooks DJ, Brundin P, Leenders KL, et al. Transplantation of fetal dopaminergic neurons in Parkinson's disease: PET 18F-fluorodopa studies in two patients with putaminal implants. Ann Neurol 1992; 31: 166-73.
70. Widner H, Tetrud J, Rehncrona S, Snow BJ, Brundin P, Gustavii B, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by MPTP. N Engl J Med 1992; 26: 1556-63.
71. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, et al. Transplantation of human fetal dopamine cells for Parkinson's disease: results at 1 year. Arch Neurol 1990; 47: 505-12.
72. Freed CR, Breeze RE, Rosemberg NL, Schneck SA, Kriek E, Qi JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327: 1549-55.
73. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327: 1541-8.
74. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38: 379-88.
75. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-24.
76. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA. Fetal nigral grafts survival and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998; 13: 383-93.
77. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Arch Neurol 1999; 56: 179-87.
78. Peschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117: 487-99.
79. Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F] fluorodopa uptake in five grafted parkinsoniano patients. Ann Neurol 1995; 38: 580-8.
80. Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients: I: clinical approach. Brain 1996; 119: 41-50.
81. López-Lozano JJ, Bravo G, Brera B, Dargallo J, Salmean J, Uria J, et al. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow-up in 10 patients. J Neurosurg 1997; 86: 931-42.
82. Kopyov OV, Jacques DS, Lieberman A, Duma CM, Rogers RL. Outcome following intraestriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp Neurol 1997; 146: 536-45.
83. Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2: 1137-40.
84. Sass KJ, Buchanan CP, Westerveld M, Marek K, Farhi A, Robbins RJ, et al. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurol 1995; 52: 680-2.
85. Price LH, Spencer DD, Marek KL, Robbins RJ, Leranth C, Farhi A, et al. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biol Psychiatry 1995; 38: 498-505.
86. Leroy A, Michelet D, Mahieux F, Geny C, Defer G, Monfort JC, et al. Neuopsychological testing of 5 patients with Parkinson's disease before and after neuron graft. Rev Neurol (Paris) 1996; 152: 158-64.
87. Antman K, Lagakos S, Drazen J. Designing and funding clinical trials of novel therapies. N Engl J Med 2001; 344: 762-3.
88. Dunnet SB, Björklund A, Lindvall O. Cell therapy in Parkinson's disease: stop or go? Nature Rev Neurosci 2001; 2: 365-9.
89. Freeman TB, Vawter DE, Leaverton PE, Godbold JH, Hauser RA, Goetz CG, et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med 1999; 341: 988-92 [correspondencia en: N Engl J Med 2000; 342: 353-5+.
90. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med 1999; 341: 992-6 [correspondencia en: N Engl J Med 2000; 342: 353-5].
91. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-9.
92. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-14.
93. Freed CR, Leehey MA, Zawada M, Bjugstad K, Thomson L, Breeze RE. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol 2003; 250 (Suppl 3): 44-6.
94. Gordon PH, Yu Q, Qualls C, Winfield H, Dillon S, Greene PE, et al. Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch Neurol 2004; 61: 858-61.
95. Trott CT, Fahn S, Greene P, Dillon S, Winfield H, Winfield L, et al. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology 2003; 60: 1938-43.
96. Folkerth RD, Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 1996; 46: 1219-25.
97. Hagell P, Piccini P, Björlund A, Brundin P, Rehncrona S, Widner H, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002; 5: 627-8.
98. Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002; 52: 628-34.
99. Wenning GK, Odin P, Morrish PK, Rehncrona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997; 42: 95-107.
100. Barker RA, Dunnett SB. Functional integration of neural grafts in Parkinson's disease. Nat Neurosci 1999: 2: 1047-8.
101. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomical, ultrastructural and metabolic studies. J Comp Neurol 1996; 370: 203-30.
102. Brundin P, Strecker RE, Widner H, Clarke DJ, Nilsson OG, Åstedt B, et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behavior, and dopamine release. Exp Brain Res 1988; 70: 192-208.
103. Emgård M, Karlsson J, Hansson O, Brundin P. Patterns of cell death and dopaminergic neurons survival in intrastriatal nigral grafts. Exp Neurol 1999; 160: 279-88.
104. Mayer E, Fawcett JW, Dunnet SB. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons. II: Effects on nigral transplants in vivo. Neuroscience 1993; 56: 389-98.
105. Rosenblad C, Martínez-Serrrano A, Björklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafs. Neuroscience 1996; 75: 979-85.
106. Yurek DM. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 1998; 153: 195-202.
107. Nakao N, Frodl EM, Duan WM, Widner H, Brundin P. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA 1994; 91: 12408-12.
108. Björklund L, Spenger C, Strömberg I. Tirilazad mesylate increases dopaminergic neuronal survival in the oculo grafting model. Exp Neurol 1997; 148: 324-33.
109. Schierle GS, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med 1999; 5: 97-100.
110. Costantini LC, Isacson O. Neuroimmunophilin ligand enhances neurite outgrowth and effect of fetal dopamine transplants. Neuroscience 2000; 100: 515-20.
111. Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000; 123: 1380-90.
112. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease: report of two cases and technical considerations. J Neurosurg 2000; 92: 863-9.
113. Hebb AO, Hebb K, Ramachandran AC, Méndez I. Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: longterm storage. J Neurosurg 2003; 98: 1078-83.
114. Lee CC, Lin SZ, Wang Y, Lin JJ, Liu JY, Chen GJ, et al. First human ventral mesencephalon and striatum cografting in a Parkinson patient. Acta Neurochir Suppl 2003; 87: 159-62.
115. Ansari AA, Mayne A, Freed CR, Breeze RE, Schneck SA, O'Brien CF, et al. Lack of detectable systemic humoral/cellular allogenic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease. Transplant Proc 1995; 27: 1401-5.
116. Méndez I, Sadi D, Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J Neurosci 1996; 16: 7216-27.
117. Baker KA, Sadi D, Hong M, Méndez I. Simultaneous intraestriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft. J Comp Neurol 2000; 426: 106-16.
118. Starr PA, Wichmann T, van Horne C, Bakay RA. Intranigral transplantation of fetal substantia nigra allograft in the hemiparkinsonian rhesus monkey. Cell Transplant 1999; 8: 37-45.
119. Collier TJ, Sortwell CS, Elsworth JD, Taylor JR, Roth RH, Sladek JR, et al. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple target grafting as a therapy for Parkinson's disease. J Comp Neurol 2002; 442: 320-30.
120. Méndez I, Dagher A, Hong M, Gaudet P, Weerasinghe S, McAlister V, et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg 2002; 96: 589-96.
121. Isacson O, Björklund L, Sánchez-Pernaute R. Parkinson's disease: interpretations of transplantation study are erroneous. Nat Neurosci 2001; 4: 553-4.